Skip to main content
Ross Tonkens, MD, Cardiology, Morrisville, NC

RossMichaelTonkensMD

Cardiology Morrisville, NC

AHA Launcher and Director, Science & Technology Accelerator Venture Capital Division

Dr. Tonkens is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Tonkens' full profile

Already have an account?

Summary

  • Director of AMERICAN HEART ASSOCIATION Science & Technology Accelerator, focused on identifying the most revolutionary, transformational, game-changing technologies and propelling them from bench to bedside where they can make the greatest positive impact on outcomes through prevention and treatment of cardiovascular disease.

Education & Training

  • Yale School of Medicine
    Yale School of MedicineClass of 1974
  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Radiology-Diagnostic
  • Cedars-Sinai Medical Center
    Cedars-Sinai Medical CenterInternship, Surgery
  • Cedars-Sinai Medical Center
    Cedars-Sinai Medical CenterResidency, Internal Medicine
  • Cedars-Sinai Medical Center
    Cedars-Sinai Medical CenterFellowship, Cardiovascular Disease
  • Yale College
    Yale CollegeB.A, Psychology

Certifications & Licensure

  • NV State Medical License
    NV State Medical License 1990 - 2019
  • CA State Medical License
    CA State Medical License 1975 - 2018

Publications & Presentations

PubMed

Journal Articles

  • The Arguments for Maintaining Professional Licensure While Working in Industry.  
    Huml, R., Tonkens, R, Regulatory Focus, pp. 48-50
  • CMC, Preclinical and Clinical Considerations for Biosimilars and Follow-on Biologics.  
    Huml, R., Hicks, P., Chance, K., Howe, K., Tonkens, R, Regulatory Affairs Focus, pp. 20-27
  • Follow-on Biologics in the EU & US.  
    Huml, R., Chance, K., Howe, K., Hicks, P., Tonkens, R, Regulatory Affairs Focus, pp. 8-13
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • A First-in-Class Oligonucleotide Drug-Antidote Pair Efficiently Modulates Factor IXa Activity in Human Subjects - A Nascent Platform for Antidote-Controlled Periproced...
    Chan, M Y, Cohen, M G, Rusconi, C P, Alexander, J H, Tonkens, R M, Harrington, R C, Becker, R C, et al, American Heart Association Annual Scientific Session
  • Antidote-Controlled Modulation of Factor IXa Activity with the First-in-Class REG1Anticoagulation System: A Randomized Phase 1 Repeat Dose Safety and Antidote Dose-Esc...
    Chan, M Y, Cohen, M G, Rusconi, C P, Tonkens R M, Harrington, R C, Becker, R C, American Heart Association Annual Scientific Session
  • Abstract 1555: Antidote-Controlled Modulation of Factor IXa Activity with the First-in- Class REG1 Anticoagulation System: A Randomized Phase 1 Repeat Dose S...
    Chan, Mark Y., Alexander, John H., Rusconi, Christopher P., Tonkens, Ross M., Harrington, Robert A., Becker, Richard C, Circulation; 116:II_323
  • Join now to see all

Other